Long COVID risks halved by dual vaccination, study finds

A volunteer draws the Astrazeneca vaccine as members of the public have their Covid-19 vaccinations at Fazl Mosque in Southfields as they host a drop in clinic on June 08, 2021 in London, England.

Dan Kitwood/Getty Images

Referenced Symbols

The risk of so-called long COVID drops nearly in half after a person receives two doses of coronavirus vaccine, according to a new study.

The study, published on Wednesday in the medical journal The Lancet, found that the odds of having symptoms for 28 days or more after post-vaccination infection were approximately halved by having two vaccine doses.

The study also found almost all symptoms were less common in vaccinated people, that more people in the vaccinated than in the unvaccinated groups were completely asymptomatic and that COVID-19 was less severe (both in terms of the number of symptoms in the first week of infection and the need for hospitalization) in participants after their first or second vaccine doses compared with unvaccinated participants.

The study was based on 1.2 million people who used a COVID symptoms app in the U.K. The country has used the vaccine jointly made by Pfizer PFE, -1.30% and BioNTech BNTX, -3.61%, as well as the Oxford-AstraZeneca AZN, -1.84% vaccine and the Moderna MRNA, -2.41% one.